Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 283

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Open access
Tan, Tiong Kit, Rijal, Pramila, Rahikainen, Rolle, Keeble, Anthony H., Schimanski, Lisa, Hussain, Saira, Harvey, Ruth, Hayes, Jack W. P., Edwards, Jane C., McLean, Rebecca K., Martini, Veronica, Pedrera, Miriam, Thakur, Nazia, Conceicao, Carina, Dietrich, Isabelle, Shelton, Holly, Ludi, Anna, Wilsden, Ginette, Browning, Clare, Zagrajek, Adrian K., Bialy, Dagmara, Bhat, Sushant, Stevenson-Leggett, Phoebe, Hollinghurst, Philippa, Tully, Matthew, Moffat, Katy, Chiu, Chris, Waters, Ryan, Gray, Ashley, Azhar, Mehreen, Mioulet, Valerie, Newman, Joseph, Asfor, Amin S., Burman, Alison, Crossley, Sylvia, Hammond, John A., Tchilian, Elma, Charleston, Bryan, Bailey, Dalan, Tuthill, Tobias J., Graham, Simon P., Duyvesteyn, Helen M. E., Malinauskas, Tomas, Huo, Jiandong, Tree, Julia A., Buttigieg, Karen R., Owens, Raymond J., Carroll, Miles W., Daniels, Rodney S., McCauley, John W., Stuart, David I., Huang, Kuan-Ying A., Howarth, Mark, Townsend, Alain R.·2021·Nature Communications

Abstract

There is need for effective and affordable vaccines against SARS-CoV-2 to tackle the ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS-CoV-2. The vaccine is based on the display of coronavirus spike glycoprotein receptor-binding domain (RBD) on a synthetic virus-like particle (VLP) platform, SpyCatcher003-mi3, using SpyTag/SpyCatcher technology. Low doses of RBD-SpyVLP in a prime-boost regimen induce a strong neutralising antibody response in mice and pigs that is superior to convalescent human sera. We evaluate antibody quality using ACE2 blocking and neutralisation of cell infection by pseudovirus or wild-type SARS-CoV-2. Using competition assays with a monoclonal antibody panel, we show that RBD-SpyVLP induces a polyclonal antibody response that recognises key epitopes on the RBD, reducing the likelihood of selecting neutralisation-escape mutants. Moreover, RBD-SpyVLP is thermostable and can be lyophilised without losing immunogenicity, to facilitate global distribution and reduce cold-chain dependence. The data suggests that RBD-SpyVLP provides strong potential to address clinical and logistic challenges of the COVID-19 pandemic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-20654-7

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Cited by

See all 283

Metadata

Authors
Tan, T. K., Rijal, P., Rahikainen, R., Keeble, A. H., Schimanski, L., Hussain, S., Harvey, R., Hayes, J. W. P., Edwards, J. C., McLean, R. K., Martini, V., Pedrera, M., Thakur, N., Conceicao, C., Dietrich, I., Shelton, H., Ludi, A., Wilsden, G., Browning, C., Zagrajek, A. K., Bialy, D., Bhat, S., Stevenson-Leggett, P., Hollinghurst, P., Tully, M., Moffat, K., Chiu, C., Waters, R., Gray, A., Azhar, M., Mioulet, V., Newman, J., Asfor, A. S., Burman, A., Crossley, S., Hammond, J. A., Tchilian, E., Charleston, B., Bailey, D., Tuthill, T. J., Graham, S. P., Duyvesteyn, H. M. E., Malinauskas, T., Huo, J., Tree, J. A., Buttigieg, K. R., Owens, R. J., Carroll, M. W., Daniels, R. S., McCauley, J. W., Stuart, D. I., Huang, K.-Y. A., Howarth, M., & Townsend, A. R.
Venue
Nature Communications
Published
2021-01-22
Volume
12
Issue
1
Pages
542-542
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3126017645
Cited by
283
References
78
FWCI
16.88
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. https://app.cochat.ai/papers/10.1038/s41467-020-20654-7
The paper
Tan, T. K., Rijal, P., Rahikainen, R., Keeble, A. H., Schimanski, L., Hussain, S., Harvey, R., Hayes, J. W. P., Edwards, J. C., McLean, R. K., Martini, V., Pedrera, M., Thakur, N., Conceicao, C., Dietrich, I., Shelton, H., Ludi, A., Wilsden, G., Browning, C., . . . Townsend, A. R. (2021). A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nature Communications. https://doi.org/10.1038/s41467-020-20654-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.